Content
Search
Navigation
Sitemap

About us
Our people
- Our people
- Board of directors
Portfolio
Sustainability
News and Insights
Investors
Contact

News

Show

Sustainability
Financial
Operating News

news from

all companies
Syncona
all Cell therapy companies
Autolus
Achilles Therapeutics
Quell Therapeutics
Resolution Therapeutics
Neogene Therapeutics
all Gene therapy companies
Freeline Therapeutics
Gyroscope Therapeutics
SwanBio Therapeutics
Purespring Therapeutics
all Biologics companies
Anaveon
all Small molecule companies
OMass Therapeutics

16.09.21

Autolus Therapeutics provides an update on its manufacturing facility in Stevenage, UK

Operating News
Cell therapy
Autolus

15.09.21

Autolus Therapeutics announces the appointment of John H. Johnson as non-executive chairman of its Board of Directors

Operating News
Cell therapy
Autolus

01.09.21

Autolus Therapeutics announces publication of obe-cel (AUTO1) Phase 1 ALLCAR19 data in adults with relapsed/ refractory B-ALL in Journal of Clinical Oncology

Operating News
Cell therapy
Autolus

09.08.21

Autolus Therapeutics Announces Promising Innovative Medicine (PIM) designation for obe-cel for the treatment of relapsed/refractory adult B-cell ALL

Operating News
Cell therapy
Autolus

05.08.21

Autolus Therapeutics Reports Second Quarter 2021 Financial Results and Operational Progress

Operating News
Cell therapy
Autolus

02.08.21

Autolus and Moderna sign Option and License Agreement for access to proprietary targeting technology from Autolus

Financial
Cell therapy
Autolus

Sign-up for company news alerts

Get the latest RNS, company news, share price information and results from Syncona

RNS alerts
Company alerts

Syncona Investment Management Limited
2nd Floor
8 Bloomsbury Street
London
WC1B 3SR

contact@synconaltd.com

About us
Our people
Portfolio
Sustainability
News and Insights
Investors
Contact

Copyright © Syncona 2021
Accessibility
Privacy & cookies
Employee privacy notice
Third party privacy notice
Regulatory publications
Modern Slavery Statement

Syncona Limited is registered in Guernsey no. 55514, registered office Arnold House, PO Box 273, St Julian’s Avenue, St Peter Port, Guernsey GY1 3RD.
Syncona Investment Management Limited is registered in England no. 10497864, 8 Bloomsbury Street, London WC1B 3SR and is authorised and regulated by the FCA. Syncona Limited is managed by Syncona Investment Management Limited.

Designed & built by SampsonMay

About us
Our people
- Our people
- Board of directors
Portfolio
Sustainability
News and Insights
Investors
Contact

GBX 177.00

Change: -2.00 (-1.12%)

Search

Search